Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study

医学 放射外科 四分位间距 危险系数 无进展生存期 脑膜瘤 比例危险模型 队列 外科 核医学 内科学 放射治疗 总体生存率 置信区间
作者
Rahul Kumar,Lucas P. Carlstrom,Ramin A. Morshed,Paul D. Brown,Nadia N. Laack,Anita Mahajan,Christopher S. Graffeo,Michael J. Link,Bruce E. Pollock
出处
期刊:Neurosurgery [Lippincott Williams & Wilkins]
卷期号:97 (6): 1267-1274
标识
DOI:10.1227/neu.0000000000003528
摘要

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) is increasingly used as a primary treatment modality for intracranial meningiomas. We aim to describe clinical outcomes after single-fraction SRS for sporadic intracranial meningiomas. METHODS: A prospectively maintained database was reviewed for patients with sporadic meningiomas who underwent SRS (Gamma Knife) as primary treatment modality from April 1997 to February 2022. Primary outcomes included progression-free survival (PFS) and treatment-related complications. RESULTS: Six hundred sixteen patients (653 tumors) underwent SRS with median follow-up of 6.3 years (interquartile range [IQR] 3.1-10.5 years). The median tumor volume was 4.5 cm 3 (IQR 2.0-8.0 cm 3 ). The median margin dose was 15.0 Gy (IQR 14.0-16.0). In-field progression was noted in 7 tumors (1.1%) and marginal progression in 2 tumors (0.3%) for a raw failure rate of 1.4%. PFS estimates at 5, 10, and 15 years were 99.8%, 99.0%, and 93.2%, respectively. Factors associated with reduced PFS on univariable analysis included older age (hazards ratio [HR] 1.14, 95% CI, 1.05-1.22, P < .001), male sex (HR 5.44, 95% CI, 1.45-20.4, P = .010), increasing tumor volume (HR 1.06, 95% CI, 0.99-1.13, P = .028), and lower tumor margin dose (HR 0.65, 95% CI, 0.43-0.97, P = .006). Treatment-related complications were noted in 56 patients (9.1%), of which 45 (7.3%) were temporary, 5 (0.8%) were minor, and 6 (1.0%) were permanent and/or required intervention. Radiosurgical parameters associated with treatment-related complications included increased number of isocenters (odds ratio [OR] 1.09, 95% CI, 1.04-1.14, P < .001), higher 12-Gy volume (OR 1.06, 95% CI, 1.03-1.09, P < .001), larger tumor volume (OR 1.06, 95% CI, 1.02-1.10, P < .001), and lower maximal dose (OR 0.90, 95% CI, 0.82-0.98, P = .11). CONCLUSION: SRS is effective as a primary treatment modality for sporadic, small-volume to medium-volume intracranial meningiomas. Pre-emptive SRS should be discussed as a safe management strategy compared with observation alone for incidentally discovered meningiomas.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甲虫完成签到,获得积分10
刚刚
1秒前
1秒前
zyt发布了新的文献求助30
2秒前
2秒前
2秒前
郝好东发布了新的文献求助10
2秒前
七一发布了新的文献求助10
3秒前
王啸岳完成签到,获得积分10
3秒前
4秒前
李爱国应助英俊的觅海采纳,获得10
6秒前
寻梦发布了新的文献求助10
6秒前
6秒前
8秒前
追光发布了新的文献求助10
8秒前
舒适的如花完成签到 ,获得积分10
9秒前
hzc发布了新的文献求助10
10秒前
乘风发布了新的文献求助10
10秒前
MildW发布了新的文献求助10
10秒前
11秒前
科研通AI6.3应助zhou采纳,获得10
13秒前
小蘑菇应助失眠的平松采纳,获得10
13秒前
14秒前
14秒前
15秒前
发发发布了新的文献求助10
15秒前
16秒前
科研通AI6.4应助miemie采纳,获得10
17秒前
传奇3应助lcj1014采纳,获得10
18秒前
18秒前
蜗牛发布了新的文献求助10
20秒前
彭于晏应助zyt采纳,获得200
20秒前
jstagey完成签到,获得积分10
20秒前
luxkex发布了新的文献求助10
21秒前
毛豆发布了新的文献求助10
22秒前
晓晓发布了新的文献求助10
23秒前
Nole应助LIU采纳,获得10
24秒前
MildW完成签到,获得积分10
24秒前
Ethanyoyo0917发布了新的文献求助10
26秒前
26秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Molecular Mechanisms of Photosynthesis, 4th Edition 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7267645
求助须知:如何正确求助?哪些是违规求助? 8888425
关于积分的说明 18787908
捐赠科研通 6944417
什么是DOI,文献DOI怎么找? 3203347
关于科研通互助平台的介绍 2376267
邀请新用户注册赠送积分活动 2179204